CENTRALIZUOTAI APMOKAMŲ VAISTINIŲ PREPARATŲ IR MPP PANAUDOJIMAS 2016 METAIS. I ketvirtį gydytas pacientų skaičius. I ketvirtį sunaudotas
|
|
- Ira Stanley
- 5 years ago
- Views:
Transcription
1 CENTRALIZUOTAI APMOKAMŲ VAISTINIŲ PREPARATŲ IR MPP PANAUDOJIMAS 016 METAIS Eil skirtas 016 m. Remicade 100 mg injekciniai buteliukai Remsima 100 mg injekciniai buteliukai Inflectra 100 mg injekciniai buteliukai M05, M06 Etanercept 5 mg injekciniai buteliukai Etanercept 50 mg injekciniai buteliukai Adalimumab Humira 40 mg injekciniai buteliukai Remicade 100 mg injekciniai buteliukai Remsima 100 mg injekciniai buteliukai Inflectra 100 mg injekciniai buteliukai M07, M45 Etanercept 5 mg injekciniai buteliukai Etanercept 50 mg injekciniai buteliukai Adalimumab Humira 40 mg injekciniai buteliukai Etanercept 5 mg injekciniai buteliukai Etanercept alfa inhibitoriai juveniliniam Etanercept 50 mg injekciniai M08 buteliukai artritui Adalimumab Humira 40 mg injekciniai buteliukai alfa inhibitoriai reumatoidiniam artritui alfa inhibitoriai psoriaziniam artritui ir ankilozuojančiam spondilitui alfa inhibitoriai Crohn'o ligai ir opiniam kolitui alfa inhibitoriai sunkiai psoriazei alfa inhibitoriai ašiniam spondiloartritui gydymui alfa inhibitoriai sunkiai vaikų psoriazei Etanercept Etanercept Remicade 100 mg injekciniai buteliukai Remsima 100 mg injekciniai buteliukai K50, K51 Inflectra 100 mg injekciniai buteliukai Adalimumab Humira 40 mg injekciniai buteliukai Remicade 100 mg injekciniai buteliukai Remsima 100 mg injekciniai buteliukai Inflectra 100 mg injekciniai buteliukai L40 Etanercept 5 mg injekciniai buteliukai Etanercept Etanercept 50 mg injekciniai buteliukai Adalimumab Humira 40 mg injekciniai buteliukai Adalimumab Humira 40 mg injekciniai M46.8 buteliukai Adalimumab Humira 40 mg injekciniai L40 buteliukai
2 Žmogaus normalusis imunodeficitams, onkohematologinėms ir kitoms ligoms skirtas 016 m. Octagam 5 g injekciniai buteliukai C90, C91.1, Octagam 10 g injekciniai buteliukai D69.3, D83, G61.0, G61.8, Kiovig 5 g injekciniai buteliukai M30.3 Kiovig 10 g injekciniai buteliukai vaistai geltonosios dėmės paburkimams, atsiradusiems Ranibizumab Lucentis,3 mg injekciniai H.1-H.9 buteliukai dėl centrinės tinklainės venos okliuzijos, vaistai diabetinės geltonosios Ranibizumab Lucentis,3 mg injekciniai E10., E11. buteliukai dėmės paburkimams vaistai amžinės geltonosios dėmės degeneracijai Specifiniai imunoglobulinai respiracinio sincitijaus viruso profilaktikai Prostaglandinai galūnių išemijai ir gangrenos prevencijai Pegiliuotas doksorubicinas kiaušidžių vėžiui Antinavikiniai vaistai (proteosomos inhibitoriai) daugybiniei mielomai Ranibizumab Lucentis,3 mg injekciniai H.3 buteliukai Aflibercept Eylea 4 mg injekciniai H.3 buteliukai Palivizumab Palivizumab Alprostadil Pegiliuotas doksorubicinas Raumenis atpalaiduojantys vaistai neurologinėms ligoms Botulino toksinas folikulinei ne Hodžkino limfomai ir stambiųjų ląstelių ne Hodžkino limfomai reumatologinėms ligoms Synagis 50 mg injekciniai Synagis 100 mg injekciniai Vasaprostan 0µg infuziniai J1.1, J0.5, J1.0 J1.1, J0.5, J1.0 I70., I73.0, I73.1, I79. buteliukai buteliukai ampulės Caelyx 0 mg injekciniai C56 buteliukai Velcade 3,5mg milteliai Sangrel 3,5mg milteliai Bortezomib C90 buteliukai Vortemyel 3,5mg milteliai Dysport 500 VV N1 G3, G4, G5, G6, G80, G81, G8, G buteliukai buteliukai C8, C83, Rituximab C91.1 buteliukai Rituximab M05, M06 buteliukai buteliukai
3 13 Vegenerio (Wegener) granuliomatozei ir mikroskopiniam poliangitui skirtas m. buteliukai Rituximab M31.3, M buteliukai Natūralūs fosfolipidai Curosurf 10 mg suspensija buteliukai neišnešiotiems naujagimiams Natūralus surfaktantas Alveofact 54 mg suspensija P.0 buteliukai Alveofact 108 mg suspensija buteliukai Antitromboziniai vaistai (fermentai) kraujotakos sutrikimams metastazavusiam gaubtinės arba tiesiosios žarnos vėžiui Tenecteplase Metalyse 40 mg N1 I1 buteliukai Metalyse 50 mg N1 I1 buteliukai Alteplase Actilyse 50 mg N1 I1, I6, I63 buteliukai Avastin 100 mg injekciniai C18-C0 buteliukai Avastin 400 mg injekciniai buteliukai Cetuximab Erbitux 100 mg injekciniai C18-C0 buteliukai nesulkialąsteliniam plaučių vėžiui Avastin 100 mg injekciniai buteliukai C Avastin 400 mg injekciniai buteliukai gimdos kaklelio vėžiui Avastin 100 mg injekciniai buteliukai C Avastin 400 mg injekciniai buteliukai plokščialąsteliniam galvos bei kaklo vėžiui Cetuximab Erbitux 100 mg injekciniai C00-C14, C3 buteliukai agresyviam skrandžio vėžiui, Trastuzumab kurio HER rodmuo yra Herceptin 150 mg injekciniai C16 buteliukai teigiamas, agresyviam krūties vėžiui, kurio HER rodmuo yra teigiamas, sunkiai psoriazei sisteminiam jaunatviniam (juvenilinaim) artritui ir jaunatviniam (juveniliniam) poliartritui reumatoidiniam artritui Trastuzumab Herceptin 150 mg injekciniai C50 buteliukai Ustekinumab Tocilizumab Stelara 45 mg injekciniai L40 buteliukai 31 Stelara 90 mg injekciniai RoActemra 80 mg M08.0- M08.9, M08.3 flakonai Tocilizumab RoActemra 80 mg M05, M06 flakonai
4 5 6 lėtinei limfocitinei leukemijai Antinavikiniai vaistiniai preparatai metastazavusiam gaubtinės ir tiesiosios žarnos vėžiui skirtas m. Obinutuzumab Gazyvaro 1000 mg C91.1 flakonai Aflibercept Zaltrap 100 mg C18-C0 flakonai Virškinimo traktą ir metabolizmą veikiantys vaistai - fermentai VI tipo Galsulfase Naglazyme 5 mg E76. buteliukai mukopolisacahridozei Antivirusiniai vaistai AIDS ligai Selektyvūs imunosupresantai, skirti išsėtinei sklerozei Tenofovir 45 mg + Emtricitabin 00 mg Tenofovir Alemtuzumab Truvada (45mg + 00mg) plėvele dengtos tabletės Viread 300 mg plėvele dengtos tabletės Lemtrada 1 mg N1 koncentratas B0, B1, B, B3, B4 tabletės tabletės G flakonai Peritoninės dializės tirpalai Neutralaus ph tirpalas rankinei ir aparatinei peritoninei dializei N18.5 Gliukopiranozės polimero tirpalas litrai litrai Aminorūgščių tirpalas litrai Medicinos pagalbos priemonės 31 Uždaro kraujo apytakos tipo dirbtinės kraujotakos sistema vnt sistemos (ECMO) suaugusiesiems vnt sistemos suaugusiesiems (ECMO) trumpesniam naudojimui Mechaninė kraujotakos palaikymo sistema suaugusiesiems I37, I06, I36, I08, I, I09, I39, I05, I, I38, I07 vnt vnt sistemos (ECMO) vaikams ir naujagimiams vnt
5 36 37 Mechaninė kraujotakos palaikymo sistema vaikams Kateterizavimo būdu implantuojami biologiniai aortos vožtuvai ir jų implantavimo sistemos bei biologiniai plaučių arterijos vožtuvai ir jų implantavimo sistemos skirtas I37, I06, I36, I08, I, I09, I39, I05, I, I38, I m. vnt vnt Biologiniai širdies vožtuvo 38 vnt protezai I06, I08, I09, I43, I05, I0, 39 Aortos šaknies protezas I07 vnt Aortos konduitas (aortos vožtuvas su dirbtine kraujagysle) Dirbtinis biologinis konduitas, skirtas protezuoti plaučių arteriją ir jos vožtuvą vnt vnt Inkstų arterijos denervacijos kateteris-elektrodas, taikomas medikamentiniam rezistentiškos arterinės hipertenzijos gydymui 43 Neurostimuliatoriai Parkinsono ligai Kochleariniai implantai, BAHA įsriegiamieji kauliniai implantai, vidurinės ausies klausos sistemos ir atsarginiai šių medicinos pagalbos priemonių procesoriai Tracheoezofaginiai kalbamieji protezai, jų priedai ir elektroniniai balso aparatai Jodo šaltiniai (I-15) prostatos vėžiui I10, I11 vnt G0 vnt H66., H66.3, H71, H74.0, H74.1, H74.4, H80., H90., H90.3, H90.5, H90.6, H90.7, H91.3, Q16.1, Q16.3 C01, C1, C13, C3, C73 vnt vnt C61 vnt Klausos aparatai H90.0- H90.8 vnt Akių protezai H44.5, H44.8, Q11.1, Q11. vnt
Drug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015
J0129 Injection, abatacept (Orencia ), 10 J0178 Injection, aflibercept (Eylea ), 1 J0256 J0257 J0585 J0586 J0587 J0588 J0597 J0641 J0717 J0800 Injection, alpha 1-proteinase inhibitor, human (Aralast NP,
More informationMedicare Part C Medical Coverage Policy
Step Therapy: Part B Medications Origination: December 19, 2018 Review Date: December 19, 2018 Next Review: December 2020 Medicare Part C Medical Coverage Policy DESCRIPTION OF PROCEDURE SERVICE Step Therapy
More informationProvider Administered Drug Program (PADP) and Physician Administered Drug VPSS List
Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List Code Drug Name Effective and/or Term Date J0129 Injection, abatacept (Orencia ), 10 mg J0178 Injection, aflibercept (Eylea
More informationPA Category Name Code(s) Additional Notes ABA 0364T 0365T 0366T 0367T 0373T 0374T H G0396. Applied Behavioral Analysis stage 3*
ABA BEHAVIORAL HEALTH CHEMICAL DEPENDENCY Applied Behavioral Analysis stage 3* Neuropsychological Testing Chemical Dependency/Substance Abuse* (MA Only) 0364T 0365T 0366T 0367T 0373T 0374T H2020 96116
More informationPA Category Name Code(s) Additional Notes ABA. Applied Behavioral Analysis stage 3*
ABA BEHAVIORAL HEALTH CHEMICAL DEPENDENCY Applied Behavioral Analysis stage 3* Neuropsychological Testing Chemical Dependency/Substance Abuse* (MA Only) 0373T H2020 96116 96112 96113 96121 96130 96131
More informationMedStar Medicare Choice Pharmacy Services
Pharmacy Services 1 MedStar Medicare Choice Pharmacy Services Table of Contents At a Glance..page 2 Pharmacy Policies..page 4 Medicare Choice Pharmacy Programs..page 6 Where to Obtain Prescriptions..page
More informationPre-authorization Form
Northwest Montana Schools Consortium 2014 Please verify services not listed below on the pre-authorization list with Benefits and Eligibility (Customer Service) to determine coverage. Preauthorization
More informationPharmacy Services Request Types
FOR DRUG REQUESTS, ONLY-- * NOTE: Only those drugs administered by a healthcare provider and billed medically would be entered via CareAffiliate. * Oral drugs would not be administered by a healthcare
More informationDate of Guidance Title of Guidance Summary of Recommendations Ratified at Croydon Time to Publication Number Prescribing Committee Implementation
NICE Technology Appraisals - Time to Implementation Report - 3 rd August 2015 Produced by Tracy Steadman, Croydon Public Health Intelligence Team, Croydon Council Date of Guidance Title of Guidance Summary
More informationMarch 2017 Pharmacy & Therapeutics Committee Decisions
UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to the UCare formulary (approved drug list). These changes are reviewed
More informationNICE-approved drugs available for use within the Trust
NICE-approved drugs available for use within the Trust The following drugs have been recommended by NICE as treatment options for the indications noted below. They are listed in the Trust Medicines Formulary
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process
Quality ID #337: Psoriasis: Tuberculosis (TB) Prevention for Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis on a Biological Immune Response Modifier National Quality Strategy Domain:
More informationManaging high-cost innovative medicines in Asia: what are the latest trends and real world practice? ISPOR Symposium September 5, 2016.
Managing high-cost innovative medicines in Asia: what are the latest trends and real world practice? ISPOR Symposium September 5, 2016 Agenda Introduction of panel members and moderator Australia China
More informationFunding Position of CCG Commissioned High Cost Drugs within Lancashire Health Economy Updated February 2016
Funding Position of CCG Commissioned High Cost Drugs within Lancashire Health Economy Updated February 2016 Drugs can only be recharged to CCGs if used in line with local or national policies as outlined
More informationList of Designated High-Cost Drugs
List of Designated High-Cost Drugs UPDATED APRIL 25, 2018 For details on the High-Cost Drug policy, see Section 5.8 of the PharmaCare Policy Manual. Recent updates appear in red. Deletions are listed at
More informationRHEUMATOID ARTHRITIS DRUGS
Rheumatology Biologics Criteria from the Exceptional Access Program RHEUMATOID ARTHRITIS DRUGS DRUG NAME BRS REIMBURSED DOSAGE FORM/ STRENGTH Adalimumab Humira 40 mg/0.8 syringe and 40mg/0.8 pen for Anakinra
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 8 Last Review Date: March 16, 2018 Orencia Description Orencia (abatacept)
More informationSPECIALTY PHARMACY Master Clinical Drug List
Abraxane J9264 Provider ONCOLOGY None NO Actemra J3262 Provider ARTHRITIS PA - all YES Acthar HP Gel J0800 Prov/Self Med/Pharm ENDOCRINE/METABOLIC PA - all YES Adagen J2504 Provider ENZYME DISORDERS None
More informationRETIRED. Maximum Drug Dose Policy
RETIRED DRUG POLICY Policy Number 2017D0034A Maximum Drug Dose Policy Annual Approval Date 3/1/2017 Approved By UnitedHealthcare National Pharmacy & Therapeutics Committee United Healthcare Community Plan
More informationAnti-HUMIRA Antibodies
Anti-HUMIRA Antibodies AbD Serotec offers you recombinant monoclonal antibodies to the human antibody adalimumab (HUMIRA). Our ready-made anti-adalimumab antibodies are ideal for preclinical research and
More informationBiologic Immunomodulators Prior Authorization with Quantity Limit Program Summary
Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary Biologic Immunomodulators Prior Authorization with Quantity Limit (with a preferred option) OBJECTIVE The intent of the
More informationDrug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases
Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy
More informationI PRIEDAS PREPARATO CHARAKTERISTIKŲ SANTRAUKA
I PRIEDAS PREPARATO CHARAKTERISTIKŲ SANTRAUKA 1 1. VAISTINIO PREPARATO PAVADINIMAS VFEND 50 mg plėvele dengtos tabletės VFEND 200 mg plėvele dengtos tabletės 2. KOKYBINĖ IR KIEKYBINĖ SUDĖTIS Vienoje tabletėje
More informationINFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 6 years of age or older 1. Moderate to severe Crohn s disease (CD) a. Patient has fistulizing disease
More informationPBS Growth. The changing composition of the PBS. PBS Top 10 drugs in transition. Shifting sands for industry as generic volume soars
PBS Growth The changing composition of the PBS PBS Top 10 drugs in transition Shifting sands for industry as generic volume soars The under co-payment market PBS Update 2014-15 Growth in PBS spending was
More informationRobust Cell-Based Assays for Detection of Neutralizing Antibodies to Follow on Biologics like Insulin, GLP1 & Avastin
Robust Cell-Based Assays for Detection of Neutralizing Antibodies to Follow on Biologics like Insulin, GLP1 & Avastin Abhi Saharia, Ph. D. Director of Marketing Bioassays in Biologics Development Research
More informationNB Drug Plans Formulary Update
Bulletin # 995 March 27, 2019 NB Drug Plans Formulary Update This update to the New Brunswick Drug Plans Formulary is effective March 27, 2019. Included in this bulletin: Special Authorization Benefit
More informationNICE TA Adherence Check list April Drug Indication NICE Approval Release Date
NICE TA Adherence Check list April 2014 Drug Indication NICE Approval Release Date Bortezomib Multiple myeloma (induction therapy) Afatinib Rituximab Pixantrone Aflibercept Teriflunomide Fluocinolone acetonide
More informationNICE TA Adherence Check List
NICE TA Adherence Check List KEY NICE TA PAS Not Terminated Indication Technology Appraisal carried out by the National Institute of Clinical Excellence - It is the process by which new and existing drugs
More informationPrice comparison of high-cost medicines 2015
Price comparison of high-cost medicines 2015 Brief report Commissioned by the Federal Ministry of Health and Women s Affairs Price comparison of high-cost medicines 2015 Brief report Authors: Sabine Vogler
More informationVaistų kūrimas Lietuvoje ir pasaulyje
Vaistų kūrimas Lietuvoje ir pasaulyje Daumantas Matulis BVTS vedėjas, Vilniaus universiteto Biotechnologijos Institutas Introduction (Miguel Fernandez) Drug Safe Effective Stable Soluble Synthesizable
More informationCenter for Evidence-based Policy
P&T Committee Brief Targeted Immune Modulators: Comparative Drug Class Review Alison Little, MD Center for Evidence-based Policy Oregon Health & Science University 3455 SW US Veterans Hospital Road, SN-4N
More informationOtezla. Otezla (apremilast) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Otezla Page: 1 of 5 Last Review Date: March 16, 2018 Otezla Description Otezla (apremilast) Background
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Otezla (apremilast) Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Otezla (apremilast) Prime Therapeutics will review Prior Authorization requests Prior
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 6 Last Review Date: March 16, 2018 Xeljanz Description Xeljanz, Xeljanz
More informationBiologics for Autoimmune Diseases
Biologics for Autoimmune Diseases Goal(s): Restrict use of biologics to OHP funded conditions and according to OHP guidelines for use. Promote use that is consistent with national clinical practice guidelines
More informationMarch 2017 P&T Updates
March 2017 P&T Updates Commercial Triple Tier 4th Tier Applicable Traditional Prior Auth DICLEGIS 3 No 2 No Yes EMVERM 2 No 2 Yes Yes Detailed s 4 tablets per day, 9 month supply per year Pinworms: 1 tablet
More informationInjectable Drugs Requiring Pre-Service Approval
Abatacept Orencia J0129, 10 mg 1500 FL LCD- L29051 1) For patients with rheumatoid arthritis with failure, intolerance or contraindications to methotrexate. Limit dosing to 40 mg Q 2 weeks. 2) For patients
More informationSTAT Bulletin. Drug Therapy Guideline Updates. To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business
STAT Bulletin November 28, 2011 Volume 9: Issue 27 To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business Drug Therapy Guideline Updates Why you re receiving this Stat
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review
More informationPublic ReimbuRsement Of PRescRiPtiOn drugs used for Off-label indications in OntaRiO By Nigel S B Rawson 1,2,3 and Arpit Chhabra 4
Original Research Public ReimbuRsement Of PRescRiPtiOn drugs used for Off-label indications in OntaRiO By Nigel S B Rawson 1,2,3 and Arpit Chhabra 4 1 Eastlake Research Group, Oakville, Ontario 2 Canadian
More informationACTEMRA/ROACTEMRA (TOCILIZUMAB) (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC498DFR PUBLICATION DATE DECEM BER 2014 ACTEMRA/ROACTEMRA (TOCILIZUMAB) (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Actemra/RoActemra (tocilizumab)
More informationGuidelines for rheumatology patients on biologic therapy. Rheumatology Department Patient Information Leaflet
Guidelines for rheumatology patients on biologic therapy Rheumatology Department Patient Information Leaflet Introduction In general, people who have biologic therapy for their rheumatic condition (e.g.
More informationIndication [previous indication was for treatment of multiple myeloma patients who received at least 2 prior therapies]
Appendix Detailed Characteristics of Supplemental s for ovel Therapeutic Agents Approved by the US Food and Drug Administration, 2005-2014 (Arranged Chronologically) Generic ame* Brand Supplemental sda
More informationGenetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School
Genetics in Cancer Therapy Raju Kucherlapati, Ph.D. Harvard Medical School RK Financial interests I do not intend to discuss an off-label use of a product during this activity AVEO Pharmaceuticals KEW
More informationPIPELINE REPORT 1ST QUARTER 2019 PIPELINE HIGHLIGHTS: Recent Approvals. Anticipated FDA Approvals. Market Launched Biosimilar Approvals
4TH QUARTER 1ST QUARTER 2019 Be in the know. Confidio is committed to helping clients anticipate pharmaceutical trends and potential shifts in medication cost management. Confidio remains informed of the
More informationInflammation, rheumatoid arthritis and cardiovascular disease
Inflammation, rheumatoid arthritis and cardiovascular disease Yvette Meißner, Pharmacoepidemiology, German Rheumatism Research Centre www. chronische-entzuendung.org Outline I. Cardiovascular disease II.
More informationSUPPLEMENTARY INFORMATION
Table S1 Therapeutic biologic product approvals, classes and innovation categories: 16 24 Approval year Trade name Active Ingredient(s) Drug class Innovation category Approval date 16 Intron-A Interferon
More informationStatinai insulto profilaktikai. Nauja kompensavimo sistema.
Statinai insulto profilaktikai. Nauja kompensavimo sistema. Dalius Jatužis VU Neurologijos ir neurochirurgijos klinika VUL Santariškių klinikos LIA konferencija, Margis, 2016-04-01 Interesų deklaracija
More informationAnti-Simponi Antibodies
Anti-Simponi Antibodies AbD Serotec offers you recombinant monoclonal antibodies to the antibody drug golimumab (Simponi). Our ready-made anti-golimumab antibodies are ideal for preclinical research and
More informationThe following are J Code requirements
The following are J Code requirements J Codes 20610 Arthrocentesis, aspiration and/or injection; major joint or bursa (eg, shoulder, hip, knee joint, subacromial bursa) A9579 Injection, gadolinium based
More informationDrug-targeted therapies and Predictive Prognosis: Changing Role for the Pathologist
Drug-targeted therapies and Predictive Prognosis: Changing Role for the Pathologist Moderator: S. Terence Dunn, Ph.D. Associate Professor, Pathology Director, Molecular Pathology Laboratory University
More informationINJECTABLE MEDICINES. Resources, Links or Additional Information. J Code Brand Names Generic names Prior Authorization or Restrictions
J9190 5-FU fluorouracil None. J0401 ABILIFY MAINTENA aripiprazole i.v. J9264 ABRAXANE paclitaxel protein bound J3262 ACTEMRA IV tocilizumab Yes, through Navitus. Restricted to (in at least consultation
More informationBCN Advantage SM requirements for drugs covered under the medical benefit
J0586 ABOBOTULINUMTOXINA Dysport X X X the medication is being used to treat J0178 AFLIBERCEPT Eylea X X X X X of Neovascular (Wet) -Related Macular Degeneration of Macular Edema following either central
More informationHigh Risk Medications
Department Policy Code: D: MM-5705 Entity: Fairview Health Services Department: Home Infusion Manual: Policies & Procedures Category: Medication Management Subject: High Risk Medications Purpose: To provide
More informationThis questionnaire was used both during the face-to-face interviews with the
Additional file 1: Primary research questionnaire This questionnaire was used both during the face-to-face interviews with the dermatologists and during the expert panel 1. During the last month, how many
More informationPARAIŠKA ĮRAŠYTI VAISTINĮ PREPARATĄ Į KOMPENSAVIMO SĄRAŠUS Nr. 1 Vilnius
Forma patvirtinta Lietuvos Respublikos sveikatos apsaugos ministro 2002 m. balandžio 5 d. įsakymu Nr. 159 (Lietuvos Respublikos sveikatos apsaugos 2015 m. birželio 2 d. įsakymo Nr. V-688 redakcija) UAB
More informationBiologic Therapies Mechanisms of Action and Treatment Considerations. CE Credit in Four Easy Steps! Speaker Disclosures 3/27/2013
Biologic Therapies Mechanisms of Action and Treatment Considerations Seth Eisenberg, RN, OCN Professional Practice Coordinator, Infusion Services Seattle Cancer Care Alliance Seattle, WA CE Credit in Four
More informationBiologic Therapies Mechanisms of Action and Treatment Considerations
Biologic Therapies Mechanisms of Action and Treatment Considerations Seth Eisenberg, RN, OCN Professional Practice Coordinator, Infusion Services Seattle Cancer Care Alliance Seattle, WA CE Credit in Four
More informationVivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19
Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19 All Non-Par Provider Requests Requires Authorization Regardless of Service J0178 J0180 J0202 J0205
More informationAPIE KRŪTIES VĖŽIO CHEMOPROFILAKTIKĄ
APIE KRŪTIES VĖŽIO CHEMOPROFILAKTIKĄ ABOUT BREAST CANCER CHEMOPREVENTION Laura Steponavičienė 1, Nadežda Lachej-Mikerovienė 1, Janina Didžiapetrienė 1,2, Eduardas Aleknavičius 3 1 Vilniaus universiteto
More informationNew Developments in Cancer Treatment. Dulcinea Quintana, MD
New Developments in Cancer Treatment Dulcinea Quintana, MD Mortality Rates Goals of treatment 1 Cure Goal of treatment 2 Prolong life Goals of treatment 3 Improve Quality of Life Goals of treatment 4
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #337: Psoriasis: Tuberculosis (TB) Prevention for Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis Patients on a Biological Immune Response Modifier National Quality Strategy
More informationBy: For: Division responsible for document: Key words: Name and job title of document author: Name and job title of document author s Line Manager:
For Use in: By: For: Guidelines for the Management of Interruption of Biologic Therapies for Division responsible for document: Key words: Name and job title of document author: Name and job title of document
More informationSTAT Bulletin. Drug Therapy Guideline Updates. To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business
STAT Bulletin November 28, 2011 Volume 17: Issue 34 To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business Drug Therapy Guideline Updates Why you re receiving this Stat
More informationSpecialty Pipeline Update
CLINICAL SOLUTIONS Drug Insights > September 2015 Specialty Pipeline Update New Drug Information Xuriden (uridine triacetate): The Food and Drug Administration (FDA) approved Wellstat Therapeutics oral
More informationPayment by Results 2013/2014 Drug and Device Exclusions
Payment by Results 2013/2014 Drug and Device Exclusions 1. Introduction The tariff payment system is nationally calculated averages. It is expected that against the tariff, providers will incur a deficit
More informationCIMZIA (certolizumab pegol)
Pre - PA Allowance None Prior-Approval Requirements Age Diagnoses 18 years of age or older Patient must have ONE of the following: 1. Moderate to severe Crohn s Disease (CD) a. Inadequate response, intolerance
More informationPercent Brand Name Generic Name Strength How Supplied NDC from AWP/SWP Adcetris. Amprya dalfampridine 10 mg 60 count bottle
Department of General Services Procurement Division Contract # 01-14- 65-57 Pharmaceutical Acquisitions Section Exhibit G-1 April 30, 2015 Walgreens Specialty Pharmacy LLC, Products Pricing Crescent Healthcare,
More informationVilė Cicėnienė, Kotryna Paulauskienė, Aurelija Trakienė
Dauginės mirties priežastys Lietuvoje 2010 m. Vilė Cicėnienė, Kotryna Paulauskienė, Aurelija Trakienė Higienos institutas Santrauka Tyrimo tikslas įvertinti pagrindinės mirties priežasties santykį su dauginėmis
More informationSIULOMO RA YTI KOMPENSAVIMO S4RA US VAISTINIO PREPARATO TERAPINES VERTES NUSTATYMO PROTOKOLAS
/ PASTU NEBUS SIUNC1AMA 2C «0t,r *0, VALSTYBINfe VAISTy KONTROLES TARNYBA PRIE LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTERIJOS Lietuvos Respublikos Sveikatos apsaugos ministerijos Ligij, vaistinii}
More informationDISCLOSURES. Online A. Infectious Complications of Monoclonal Antibody Therapies 6/22/2012. Cytokine blocking. Lymphocyte depleting.
Online A Infectious Complications of Monoclonal Antibody Therapies Steven M. Holland, M.D. Off-Label Usage None DISCLOSURES Financial Relationships with Relevant Commercial Interests None Resolution: N/A
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi
More informationPharmacy and Medical Guideline Updates
STAT Bulletin PO Box 15013 Albany, New York 12212 August 2, 2010 Volume 8: Issue 19 To: All PCPs and Specialists Contracts Affected: All Lines of Business Pharmacy and ical Guideline Updates As a result
More informationIntroduction to Targeted Therapy
Introduction to Targeted Therapy Cancer remains the second leading cause of death in the United States, despite the significant advances in cancer therapy made over the past several decades. Many factors
More informationTechnology appraisal guidance Published: 26 January 2016 nice.org.uk/guidance/ta375
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed Technology
More informationRemicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximababda)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.02 Subject: Infliximab Page: 1 of 13 Last Review Date: December 8, 2017 Infliximab Description Remicade
More informationPraktinės informacijos apie Opdivo vartojimą pacientai turėtų ieškoti pakuotės lapelyje arba kreiptis į savo gydytoją ar vaistininką.
EMA/691693/2017 EMEA/H/C/003985 EPAR santrauka plačiajai visuomenei nivolumabas Šis dokumentas yra Europos viešo vertinimo protokolo (EPAR) santrauka. Jame paaiškinama, kaip agentūra vertino vaistą, kad
More informationCriteria for Medical Benefit Drugs Requiring Clinical Review
Note: Authorization of a service based on the clinical information provided does not guarantee payment. The claim must be properly submitted and the member must be eligible on the date of service for the
More information2017 PERIOPERATIVE MEDICINE SYMPOSIUM Peri-operative use of immunosuppression in rheumatology patients
2017 PERIOPERATIVE MEDICINE SYMPOSIUM Peri-operative use of immunosuppression in rheumatology patients Dr Alberta Hoi Rheumatologist MBBS, FRACP, PhD NEW ERA IN MUSCULOSKELETAL MEDICINE New drugs - Biologics,
More informationACTEMRA (tocilizumab)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 1. Active Polyarticular Juvenile Idiopathic Arthritis (PJIA) b. Patient has an intolerance or has experienced
More informationCriteria for Medical Benefit Drugs Requiring Clinical Review
Note: Authorization of a service based on the clinical information provided does not guarantee payment. The claim must be properly submitted and the member must be eligible on the date of service for the
More informationBiologics in rheumatic diseases
Biologics in rheumatic diseases Dimitrios A. Vassilopoulos, MD Joint Rheumatology Program Clinical Immunology-Rheumatology Unit 2 nd Department of Medicine and Laboratory National and Kapodistrian University
More informationIncidence and risk factors for early postoperative cognitive decline after coronary artery bypass grafting
460 Medicina (Kaunas) 2010;46(7):460-4 Incidence and risk factors for early postoperative cognitive decline after coronary artery bypass grafting Ieva Norkienė 1, Robertas Samalavičius 1, Irina Misiūrienė
More informationPhase 2b dose selection, leveraging comparator data through multidisciplinary modeling & simulation
Phase 2b dose selection, leveraging comparator data through multidisciplinary modeling & simulation Thomas Kerbusch Thomas Kerbusch* (1), Russ Wada (2), Anthe Zandvliet (1), Kuenhi Tsai (6), Jing Su (6),
More informationVI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Incidence: The incidence of acute and delayed N&V was investigated in highly and moderately emetogenic
More informationAvastin. Avastin (bevacizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.04 Subject: Avastin Page: 1 of 9 Last Review Date: September 15, 2017 Avastin Description Avastin
More informationAzacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded
Provincial Fundin Summary The interim Joint Oncoloy Dru Review (ijodr) was the precursor oncoloy dru review process prior to pcodr, which provided evidence-based recommendation for cancer treatments from
More informationBasic Approach/Goals. Medical Management of Rheumatic Diseases. Acetaminophen. Anti-inflammatories (NSAIDs) Steroids.
Basic Approach/Goals Medical Management of Rheumatic Diseases Diane Lacaille, Rheumatologist ACE Workshop April 23, 2018 1) Symptom control: Acetaminophen, NSAIDs, steroids (intraart, po) 2) Prevention
More informationCosentyx. Cosentyx (secukinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.11 Subject: Cosentyx Page: 1 of 7 Last Review Date: September 20, 2018 Cosentyx Description Cosentyx
More informationAvastin. Avastin (bevacizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.04 Subject: Avastin Page: 1 of 9 Last Review Date: June 22, 2017 Avastin Description Avastin (bevacizumab)
More informationHiperglikeminės būklės
Hiperglikeminės būklės Diagnostika ir gydymo principai, VGPUL Galima kopijuoti ir platinti 1 Cukrinis diabetas Multietiologinis metabolinis sutrikimas, kurio metu stebima lėtinė hiperglikemija su angliavandenių,
More informationRegulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.12 Subject: Entyvio Page: 1 of 7 Last Review Date: September 20, 2018 Entyvio Description Entyvio
More informationCyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65
Market DC Cyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65 Override(s) Prior Authorization Quantity Limit Medications Cyltezo (adalimumab-adbm) 40 mg/0.8 ml prefilled syringe #* ^ Approval Duration 1 year
More informationThe Economic$ and Epidemiology of Intravitreal Injections
The Economic$ and Epidemiology of Intravitreal Injections 2016 Proctor Lecture I have the following financial interests or relationships to disclose: Alcon Laboratories, Inc.: Consultant/Advisor Allergan,
More informationPrior Auth Form Page Number
Prior Auth Form Page Number B vs D Oral Anti-Cancer 3 B vs D Oral Anti-Emetic 4 B vs D Oral Anti-rejection/Transplant 5 J0129 Abatacept, inj Orencia 6 J0180 Agalsidase beta injection Fabrazyme 7 J0205
More informationREFERENCE CODE GDHC497DFR PUBLICAT ION DATE DECEMBER 2014 ORENCIA (ABATACEPT) (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC497DFR PUBLICAT ION DATE DECEMBER 2014 ORENCIA (ABATACEPT) (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Orencia (abatacept) in the 10MM (US,
More information